Immunocore Holdings plc – ADR | Small-cap | Healthcare
$32.01
0.00%
| Immunocore Holdings Stock Comparison:
Immunocore Holdings vs VertexImmunocore Holdings vs RegeneronImmunocore Holdings vs Vera TherapeuticsImmunocore Holdings vs AgiosImmunocore Holdings vs Amicus TherapeuticsImmunocore Holdings vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 310.2M
Gross Profit 307.5M 99.12%
Operating Income -70.5M -22.71%
Net Income -51.1M -16.47%
EPS (Diluted) -$1.02

Balance Sheet Metrics

Total Assets 1.0B
Total Liabilities 648.8M
Shareholders Equity 360.7M
Debt to Equity 1.80

Cash Flow Metrics

Operating Cash Flow -23.7M
Free Cash Flow 20.9M

Revenue & Profitability Trend

Immunocore Holdings Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 310.2M 249.4M 174.4M 36.5M 41.0M
Cost of Goods Sold 2.7M 1.0M 1.1M 0 0
Gross Profit 307.5M 248.4M 173.3M 36.5M 41.0M
Operating Expenses 377.9M 308.0M 225.0M 211.1M 162.7M
Operating Income -70.5M -59.6M -51.7M -174.6M -121.7M
Pre-tax Income -52.9M -60.9M -40.9M -179.9M -119.1M
Income Tax -1.8M -5.6M 11.7M 150.0K -18.1M
Net Income -51.1M -55.3M -52.5M -180.0M -101.0M
EPS (Diluted) -$1.02 -$1.13 -$1.09 -$4.05 -$3.18

Income Statement Trend

Immunocore Holdings Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 929.9M 528.8M 474.0M 354.6M 208.4M
Non-Current Assets 79.6M 68.2M 52.8M 52.7M 60.3M
Total Assets 1.0B 597.0M 526.8M 407.3M 268.7M
Liabilities
Current Liabilities 212.2M 139.0M 100.8M 82.6M 75.0M
Non-Current Liabilities 436.6M 89.1M 87.0M 93.2M 118.4M
Total Liabilities 648.8M 228.2M 187.9M 175.8M 193.3M
Equity
Total Shareholders Equity 360.7M 368.8M 338.9M 231.5M 75.4M

Balance Sheet Composition

Immunocore Holdings Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -51.1M -55.3M -52.5M -180.0M -101.0M
Operating Cash Flow -23.7M -58.5M -67.0M -167.9M -132.2M
Investing Activities
Capital Expenditures -5.1M -5.4M -2.2M -1.3M -2.8M
Investing Cash Flow -355.1M -5.4M 689.3K -1.3M 1.6M
Financing Activities
Dividends Paid - - 0 0 0
Financing Cash Flow 337.1M 0 135.7M 265.9M 158.3M
Free Cash Flow 20.9M -2.5M -51.4M -144.5M -87.7M

Cash Flow Trend

Immunocore Holdings Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -31.41
Forward P/E -18.20
Price to Book 4.13
Price to Sales 4.69
PEG Ratio -18.20

Profitability Ratios

Profit Margin -6.48%
Operating Margin -3.85%
Return on Equity -5.86%
Return on Assets -1.83%

Financial Health

Current Ratio 6.36
Debt to Equity 114.67
Beta 0.84

Per Share Data

EPS (TTM) -$0.43
Book Value per Share $7.54
Revenue per Share $6.67

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
imcr 1.6B -31.41 4.13 -5.86% -6.48% 114.67
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Vera Therapeutics 1.4B -8.41 2.58 -39.49% 0.00% 10.18
Agios 1.9B 2.89 1.32 60.26% 1,798.26% 3.61
Amicus Therapeutics 1.8B -31.56 9.08 -18.12% -5.41% 229.11

Financial data is updated regularly. All figures are in the company's reporting currency.